Table 1.
Patient characteristics for MS patients with RT
| Patient no. | Age | Gender | Underlying disease | GS site for radiotherapy | Timing of GS emergence | Cytogenetics |
|---|---|---|---|---|---|---|
| 1 |
62 |
F |
AML-M2 |
Skin |
Relapse after chemotherapy, BM also (+) |
Normal |
| 2 |
50 |
M |
CML |
Anus |
CML in blast crisis |
47 XXY, inv(11) |
| 3 |
83 |
M |
AML-M4 |
Skin |
Found at initial presentation with BM (+) |
t(2;14), NPM(-), FLT3(-) |
| 4 |
55 |
M |
AML-M1 |
Spinal cord |
Relapse after chemotherapy, BM also (+) |
t(9;22) Philadelphia chromosome (+) |
| 5 |
58 |
M |
AML-M1 |
Skin (7 lesions) |
Relapse after BMT, BM also (+) |
Normal |
| 6 |
6 |
F |
CML |
Bone (right femur) |
CML in blast crisis |
t(9;22) Philadelphia chromosome (+) |
| 7 |
71 |
F |
MDS- RAEB 2 |
Brain |
- |
Normal |
| 8 |
41 |
F |
AML-M2 |
Cervix |
Relapse after BMT, BM (-) |
t(8;21) |
| |
|
|
|
Right breast |
Relapse after BMT, BM (-) |
|
| 9 |
42 |
M |
de novo sarcoma |
Right nipple |
Found at presentation, BM (-) |
Normal |
| |
|
|
|
Brain |
Relapse after chemotherapy, BM also (+) |
|
| |
|
|
|
Paranasosinus |
Relapse after chemotherapy, BM also (+) |
|
| 10 |
56 |
M |
CML |
Spinal cord |
CML in blast crisis |
Normal |
| 11 |
22 |
M |
AML-M4 |
Skin (11 lesions) |
Relapse after BMT, BM (-) |
del(1)(p32p36), t(10;11)(p13;q13) |
| 12 |
44 |
F |
CML |
Right breast |
CML in blast crisis receiving BMT. relapse after BMT, BM (-) |
Normal |
| 13 |
75 |
F |
AML-M2 |
Skin |
Found at initial presentation with BM (+) |
del(15)(q22q35) |
| 14 |
29 |
F |
AML-M2 |
Pituitary gland |
Relapse after BMT, BM (-) |
Normal |
| 15 |
32 |
F |
AML-M1 |
Right breast |
Relapse after BMT, BM (-) |
Normal |
| |
|
|
|
Left breast |
Relapse after BMT, BM (-) |
|
| 16 |
47 |
M |
AML-M1 |
Brain |
Relapse after chemotherapy, BM also (+) |
Normal |
| |
|
|
|
Spinal cord |
Relapse after chemotherapy, BM also (+) |
|
| 17 |
47 |
F |
AML-M2 |
Skin |
Relapse after chemotherapy, BM also (+) |
t(8;21) |
| 18 |
40 |
M |
AML-M5 |
Skin |
Emerging during chemotherapy and persistent after BMT, BM (+) |
-3p,t(5;17)(q15;q22), t(11;19)(q23;p13),-17,19p; der(19)t(17;19)(q11;p11), t(11;12)(p15;q13), NPM(-), FLT3(-) |
| 19 |
42 |
F |
AML-M1 |
Right inguinal area |
Found at initial presentation with BM (+) |
Normal |
| 20 |
4 |
M |
AML-M2 |
Bone (left tibia) |
Relapse after BMT, BM also (+) |
t(8;21), AML1-ETO fusion transcription (+) |
| |
|
|
|
Left buccal mucosa |
Relapse after BMT, BM also (+) |
|
| Bone (right foot) | Relapse after BMT, BM also (+) |
Abbreviations: AML = acute myeloid leukemia; BM = bone marrow; BMT = bone marrow transplant; CML = chronic myeloid leukemia; FLT3 = FMS-like tyrosine kinase 3; MDS = myelodysplastic syndrome; NPM = nucleophosmin; RAEB = refractory anemia with excess blasts.